Amiodarone Hydrochloride
FDA-approved product (tablet, oral), marketed as Amiodarone Hydrochloride, Cordarone, Nexterone and 1 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cardiac arrhythmia
- Ventricular arrhythmia
- Ventricular fibrillation
- Ventricular tachycardia
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Antiarrhythmics, class iii
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA43.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli33.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae21.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis56.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Amiodarone Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Pharmacological Intervention to Prevent NOAF After TAVR
NCT07519161 · start 2026-04-07
Registered record
- Registry ID
- NCT07519161
- Conditions
- Atrial Fibrillation
- Interventions
- Metoprolol succinate; Amiodarone
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Not yet recruiting
- Start
- 2026-04-07
- Completion
- 2030-03-31
- Enrolment
- 198
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAtrial FibrillationInterventionMetoprolol succinate; AmiodaronePhaseNot applicableRegistry statusNot yet recruitingEfficacy of Early Rhythm Control in AF With TR Patients
NCT07607093 · start 2026-02-18
Registered record
- Registry ID
- NCT07607093
- Conditions
- Atrial Fibrillation (AF); Tricuspid Regurgitation (TR)
- Interventions
- Anti-arrhythmic drugs for rhythm control; DC cardioversion, catheter ablation for rhythm control; Usual care
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Recruiting
- Start
- 2026-02-18
- Completion
- 2027-02-28
- Enrolment
- 5,800
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAtrial Fibrillation (AF); Tricuspid Regurgitation (TR)InterventionAnti-arrhythmic drugs for rhythm control; DC cardioversion, catheter ablation for rhythm control; Usual carePhaseNot recordedRegistry statusRecruitingEarly Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE
NCT05293080 · start 2025-11-06
Registered record
- Registry ID
- NCT05293080
- Conditions
- Acute Ischemic Stroke; Atrial Fibrillation
- Interventions
- Medical or interventional therapy for rhythm control in atrial fibrillation (antiarrhythmic drugs, ablation, electric cardio version); Usual care for atrial fibrillation
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Recruiting
- Start
- 2025-11-06
- Completion
- 2031-09
- Enrolment
- 1,746
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Ischemic Stroke; Atrial FibrillationInterventionMedical or interventional therapy for rhythm control in atrial fibrillation (antiarrhythmic drugs, ablation, electric cardio version); Usual care for atrial fibrillationPhasePhase 3Registry statusRecruitingDrug-Drug Interaction of JMKX003142 With Amiodarone and Febuxostat in Healthy Subjects
NCT07181265 · start 2025-10-30
Registered record
- Registry ID
- NCT07181265
- Conditions
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Interventions
- Amiodarone Hydrochloride Tablets; Febuxostat Tablets
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Not yet recruiting
- Start
- 2025-10-30
- Completion
- 2026-06-30
- Enrolment
- 48
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAutosomal Dominant Polycystic Kidney Disease (ADPKD)InterventionAmiodarone Hydrochloride Tablets; Febuxostat TabletsPhasePhase 1Registry statusNot yet recruitingMinocycline Plus Amiodarone Versus Amiodarone Alone for the Prevention of Atrial Fibrillation After Cardiac Surgery
NCT01422148 · start 2025-07
Registered record
- Registry ID
- NCT01422148
- Conditions
- Atrial Fibrillation
- Interventions
- Amiodarone; Minocycline
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Not yet recruiting
- Start
- 2025-07
- Completion
- 2028-01-24
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAtrial FibrillationInterventionAmiodarone; MinocyclinePhasePhase 2Registry statusNot yet recruitingCircumferential Pulmonary Vein Isolation Plus Transition Zone Modification in Atrial Fibrillation Patients Without Low-Voltage Areas
NCT06930599 · start 2025-04-09
Registered record
- Registry ID
- NCT06930599
- Conditions
- Atrial Fibrillation (AF)
- Interventions
- Pulmonary vein isolation plus transition zone modification; Pulmonary vein isolation alone
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Not yet recruiting
- Start
- 2025-04-09
- Completion
- 2026-10-09
- Enrolment
- 162
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAtrial Fibrillation (AF)InterventionPulmonary vein isolation plus transition zone modification; Pulmonary vein isolation alonePhaseNot applicableRegistry statusNot yet recruitingPacing of Left Bundle Branch Area and Atroventricular Node ablatIon in Patients With Symptomatic Atrial Fibrillation
NCT06699342 · start 2025-01-27
Registered record
- Registry ID
- NCT06699342
- Conditions
- Atrial Fibrillation (AF)
- Interventions
- Pacemaker implantation with Left bundle branch area pacing (LBBAP); Atrioventricular node ablation (AVNA); Pharmacologic therapy optimized for Atrial Fibrillation management
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Recruiting
- Start
- 2025-01-27
- Completion
- 2027-12-31
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAtrial Fibrillation (AF)InterventionPacemaker implantation with Left bundle branch area pacing (LBBAP); Atrioventricular node ablation (AVNA); Pharmacologic therapy optimized for Atrial Fibrillation managementPhaseNot applicableRegistry statusRecruitingCAB Versus Medical Therapy in Patients With AF and HF With Different EF Categories
NCT05364866 · start 2022-05-01
Registered record
- Registry ID
- NCT05364866
- Conditions
- Cardiovascular Diseases
- Interventions
- Antiarrhythmic drug Therapy; cryoballoon ablation
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Unknown
- Start
- 2022-05-01
- Completion
- 2024-12-31
- Enrolment
- 200
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCardiovascular DiseasesInterventionAntiarrhythmic drug Therapy; cryoballoon ablationPhaseNot recordedRegistry statusUnknownProphylaxis for Patients at Risk to Eliminate Post-operative Atrial Fibrillation
NCT04392921 · start 2022-03-07
Registered record
- Registry ID
- NCT04392921
- Conditions
- Atrial Fibrillation
- Interventions
- Amiodarone; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2022-03-07
- Completion
- 2024-04
- Enrolment
- 80
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAtrial FibrillationInterventionAmiodarone; PlaceboPhaseNot applicableRegistry statusUnknownOral Amiodarone for Acute Cardioversion of Atrial Fibrillation Study
NCT04594746 · start 2022-02-03
Registered record
- Registry ID
- NCT04594746
- Conditions
- Atrial Fibrillation
- Interventions
- Amiodarone Hydrochloride; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Terminated
- Start
- 2022-02-03
- Completion
- 2026-01-20
- Enrolment
- 3
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAtrial FibrillationInterventionAmiodarone Hydrochloride; PlaceboPhasePhase 4Registry statusTerminatedRefralon Versus Amiodarone for Cardioversion of Paroxysmal Fibrillation and Atrial Flutter
NCT05445297 · start 2022-01-26
Registered record
- Registry ID
- NCT05445297
- Conditions
- Atrial Fibrillation Paroxysmal
- Interventions
- Pharmacological cardioversion with Amiodarone; Pharmacological cardioversion with Refralon
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2022-01-26
- Completion
- 2023-06-30
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAtrial Fibrillation ParoxysmalInterventionPharmacological cardioversion with Amiodarone; Pharmacological cardioversion with RefralonPhasePhase 4Registry statusCompletedCatgut Embedding in Acupoints on Treating Persistent Atrial Fibrillation After Catheter Ablation
NCT05125042 · start 2021-12-01
Registered record
- Registry ID
- NCT05125042
- Conditions
- Persistent Atrial Fibrillation
- Interventions
- Amiodarone hydrochloride tablet + acupoint catgut embedding; Amiodarone hydrochloride tablet
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2021-12-01
- Completion
- 2023-12-20
- Enrolment
- 120
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPersistent Atrial FibrillationInterventionAmiodarone hydrochloride tablet + acupoint catgut embedding; Amiodarone hydrochloride tabletPhaseNot applicableRegistry statusUnknownUsing Cryoballoon Ablation as Initial Treatment for Persistent Atrial Fibrillation
NCT04942834 · start 2021-10-01
Registered record
- Registry ID
- NCT04942834
- Conditions
- Atrial Fibrillation, Persistent; Arrhythmias, Cardiac
- Interventions
- Antiarrhythmic drug including Propafenone, Sotalol, Dronedarone and Amiodarone; cryoballoon ablation
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2021-10-01
- Completion
- 2025-08-23
- Enrolment
- 320
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAtrial Fibrillation, Persistent; Arrhythmias, CardiacInterventionAntiarrhythmic drug including Propafenone, Sotalol, Dronedarone and Amiodarone; cryoballoon ablationPhaseNot applicableRegistry statusCompletedSystematic Review and Meta-Analysis of Multaq® for Safety in Atrial Fibrillation
NCT05279833 · start 2021-09-24
Registered record
- Registry ID
- NCT05279833
- Conditions
- Atrial Fibrillation
- Interventions
- dronedarone; sotalol
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2021-09-24
- Completion
- 2022-03-31
- Enrolment
- 87,810
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAtrial FibrillationInterventiondronedarone; sotalolPhaseNot recordedRegistry statusCompletedProphylactic Amiodarone for Shockable Cardiac Arrest
NCT04845607 · start 2021-04-01
Registered record
- Registry ID
- NCT04845607
- Conditions
- Cardiac Arrest; Ventricular Arrythmia
- Interventions
- Amiodarone Injection
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Unknown
- Start
- 2021-04-01
- Completion
- 2023-02-28
- Enrolment
- 302
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCardiac Arrest; Ventricular ArrythmiaInterventionAmiodarone InjectionPhasePhase 3Registry statusUnknown